Literature DB >> 18709027

The case / progressive hypertension and proteinuria on anti-angiogenic therapy.

Jagdeep S Obhrai1, Tejas V Patel, Benjamin D Humphreys.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18709027      PMCID: PMC3435429          DOI: 10.1038/ki.2008.288

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


× No keyword cloud information.
  4 in total

Review 1.  Preeclampsia and angiogenic imbalance.

Authors:  Sharon Maynard; Franklin H Epstein; S Ananth Karumanchi
Journal:  Annu Rev Med       Date:  2008       Impact factor: 13.739

2.  A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.

Authors:  Tejas V Patel; Jeffrey A Morgan; George D Demetri; Suzanne George; Robert G Maki; Michael Quigley; Benjamin D Humphreys
Journal:  J Natl Cancer Inst       Date:  2008-02-12       Impact factor: 13.506

3.  Autocrine VEGF signaling is required for vascular homeostasis.

Authors:  Sunyoung Lee; Tom T Chen; Chad L Barber; Maria C Jordan; Jared Murdock; Sharina Desai; Napoleone Ferrara; Andras Nagy; Kenneth P Roos; M Luisa Iruela-Arispe
Journal:  Cell       Date:  2007-08-24       Impact factor: 41.582

4.  VEGF inhibition and renal thrombotic microangiopathy.

Authors:  Vera Eremina; J Ashley Jefferson; Jolanta Kowalewska; Howard Hochster; Mark Haas; Joseph Weisstuch; Catherine Richardson; Jeffrey B Kopp; M Golam Kabir; Peter H Backx; Hans-Peter Gerber; Napoleone Ferrara; Laura Barisoni; Charles E Alpers; Susan E Quaggin
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

  4 in total
  6 in total

1.  The anti-tumorigenic properties of peroxisomal proliferator-activated receptor alpha are arachidonic acid epoxygenase-mediated.

Authors:  Ambra Pozzi; Vlad Popescu; Shilin Yang; Shaojun Mei; Mingjian Shi; Satu M Puolitaival; Richard M Caprioli; Jorge H Capdevila
Journal:  J Biol Chem       Date:  2010-02-23       Impact factor: 5.157

2.  Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature.

Authors:  Rebecca L Ruebner; Lawrence Copelovitch; Nicholas F Evageliou; Michelle R Denburg; Jean B Belasco; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2013-12-07       Impact factor: 3.714

3.  Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo.

Authors:  Jun-Yan Liu; See-Hyoung Park; Christophe Morisseau; Sung Hee Hwang; Bruce D Hammock; Robert H Weiss
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

4.  PPARα activation can help prevent and treat non-small cell lung cancer.

Authors:  Nataliya Skrypnyk; Xiwu Chen; Wen Hu; Yan Su; Stacey Mont; Shilin Yang; Mahesha Gangadhariah; Shouzuo Wei; John R Falck; Jawahar Lal Jat; Roy Zent; Jorge H Capdevila; Ambra Pozzi
Journal:  Cancer Res       Date:  2013-12-03       Impact factor: 12.701

5.  Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea.

Authors:  Seon Ha Baek; Hyunsuk Kim; Jeonghwan Lee; Dong Ki Kim; Kook-Hwan Oh; Yon Su Kim; Jin Suk Han; Tae Min Kim; Se-Hoon Lee; Kwon-Wook Joo
Journal:  Korean J Intern Med       Date:  2014-01-02       Impact factor: 2.884

6.  Collapsing Glomerulopathy and Thrombotic Microangiopathy in Postpartum Period: Two Case Reports.

Authors:  N Gopalakrishnan; J Dhanapriya; C Padmakumar; T Dineshkumar; A A Kurien; R Sakthirajan; T Balasubramaniyan
Journal:  Indian J Nephrol       Date:  2018 Mar-Apr
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.